My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 91

    1.

    Metastatic duodenal GIST: role of surgery combined with imatinib mesylate.

    Mohiuddin K, Nizami S, Munir A, Memon B, Memon MA.

    Int Semin Surg Oncol. 2007 Mar 29;4:9.PMID: 17391535 [PubMed]Free PMC ArticleFree textRelated citations

    2.

    Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.

    Anticancer Drugs. 2008 Jul;19(6):607-12.PMID: 18525320 [PubMed - indexed for MEDLINE]Related citations

    3.

    Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

    Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG.

    Ann Surg. 2007 Mar;245(3):341-6.PMID: 17435538 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

    4.

    Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy.

    Choi WH, Kim S, Hyung WJ, Yu JS, Park CI, Choi SH, Noh SH.

    Yonsei Med J. 2009 Jun 30;50(3):437-40. Epub 2009 Jun 23.PMID: 19568608 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

    5.

    Gastric GISTs. Personal experience.

    Mingolla GP, Riccio PA, Linguerri R, La Donna M, Zannelli M, Artuso S.

    Ann Ital Chir. 2007 Jul-Aug;78(4):283-8; discussion 288-9.PMID: 17990602 [PubMed - indexed for MEDLINE]Related citations

    6.

    Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST).

    Hohenberger P, Eisenberg B.

    Ann Surg Oncol. 2010 Apr 21. [Epub ahead of print]PMID: 20407930 [PubMed - as supplied by publisher]Related citations

    7.

    Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

    Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.

    J Clin Oncol. 2008 Feb 1;26(4):626-32.PMID: 18235122 [PubMed - indexed for MEDLINE]Related citations

    8.

    Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report.

    Bhattacharya S, Choudhury AK, Ravi S, Morrissey J, Mathew G.

    J Med Case Reports. 2008 Apr 18;2:110.PMID: 18423008 [PubMed]Free PMC ArticleFree textRelated citations

    9.

    A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

    McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC.

    Ann Surg Oncol. 2009 Apr;16(4):910-9. Epub 2008 Oct 25.PMID: 18953611 [PubMed - indexed for MEDLINE]Related citations

    10.

    Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case.

    Ludvigsen L, Toxvaerd A, Mahdi B, Krarup-Hansen A, Bergenfeldt M.

    Surg Today. 2007;37(12):1105-9. Epub 2007 Nov 26.PMID: 18030576 [PubMed - indexed for MEDLINE]Related citations

    11.

    Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

    Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A.

    Eur J Surg Oncol. 2009 Jul;35(7):739-45. Epub 2008 Dec 24.PMID: 19110398 [PubMed - indexed for MEDLINE]Related citations

    12.

    Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

    Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.

    J Clin Oncol. 2008 Feb 1;26(4):620-5.PMID: 18235121 [PubMed - indexed for MEDLINE]Related citations

    13.

    Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.

    An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK, Kim S.

    Eur J Surg Oncol. 2007 Oct;33(8):1030-5. Epub 2007 Apr 10.PMID: 17428635 [PubMed - indexed for MEDLINE]Related citations

    14.

    'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.

    Sevinc A, Camci C.

    Chemotherapy. 2009;55(1):11-4. Epub 2008 Oct 31.PMID: 18974643 [PubMed - indexed for MEDLINE]Related citations

    15.

    Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

    J Clin Oncol. 2008 Nov 20;26(33):5360-7. Epub 2008 Oct 27.PMID: 18955451 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

    16.

    Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.

    McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC.

    Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6727-34.PMID: 18006774 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    17.

    Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

    Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK.

    J Surg Oncol. 2008 Jul 1;98(1):27-33.PMID: 18452195 [PubMed - indexed for MEDLINE]Related citations

    18.

    Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team.

    Lancet. 2009 Mar 28;373(9669):1097-104. Epub 2009 Mar 18. Erratum in: Lancet. 2009 Aug 8;374(9688):450. PMID: 19303137 [PubMed - indexed for MEDLINE]Related citations

    19.

    Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.

    Zhu J, Wang Y, Hou M, Li HY, Zhang J.

    Oncology. 2007;73(5-6):324-7. Epub 2008 May 23.PMID: 18497504 [PubMed - indexed for MEDLINE]Related citations

    20.

    [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib]

    Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM.

    Rev Esp Med Nucl. 2008 May-Jun;27(3):168-75. Spanish. PMID: 18570858 [PubMed - indexed for MEDLINE]Related citations

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    You are here: NCBI > Literature > PubMed
    Write to the Help Desk